Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Solid Tumor: early-phase trial registry
10 of 14 indexed Locally Advanced Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 10 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Locally Advanced Solid Tumor: 14 US clinical trials tracked, 10 recruiting.
Locally Advanced Solid Tumor is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Nuvalent, running 3 of these trials.
Enrollment posture brief
Registry condition locally-advanced-solid-tumor
OPEN 10 | RECR 71% | LATE 0 | EARLY 14 | RANK #1230 | SPON 3
Volume-matched condition peers
Nearest open-share peer: ACL Tear (71% recruiting · 7 trials)
Locally Advanced Solid Tumor lists 10 open slots (71% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced Solid Tumor is recruiting above its size-band peers.
10 of 14 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Locally Advanced Solid Tumor research.
Nuvalent accounts for 3 of 14 trials (21.4%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Locally Advanced Solid Tumor enrolment sits around 192 participants.
Median target enrolment is 192 among the 14 trials that report a genuine target (sentinel values excluded). 5 of those (35.7%) plan for fewer than 100 participants.
-
Locally Advanced Solid Tumor research is mostly interventional.
14 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent
NCT05384626
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines
NCT05919264
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Nuvalent
NCT05118789
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics
NCT05732831
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent
NCT06521554
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
NCT07213817
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics
NCT05378425
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
University of Cincinnati
NCT06416007
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Acepodia Biotech
NCT06415487
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
University of Utah
NCT06358677
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Ascendis Pharma Oncology Division A/S
NCT05081609
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics
NCT05275478
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co.
NCT05731271
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio
NCT04050709
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced Solid Tumor page
14 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Locally Advanced Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nuvalent sponsors the most Locally Advanced Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Nuvalent's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Solid Tumor condition card totals 14 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.